In the News

BOSTON, MA – October 24, 2025 (Via PR NewsWire) – Intrinsic Therapeutics, Inc., the makers of the Barricaid® Annular Closure Device, announced today that the American Medical Association (AMA) has published a new Category I CPT® code, 63032, for bone-anchored annular closure, effective January 1, 2026. This new add-on CPT code specifically describes the adjunctive […]

BOSTON, MA – September 10, 2025 – Intrinsic Therapeutics, Inc., is a medical technology company committed to redefining the standard of care for lumbar discectomy patients with large annular defects by reducing reoperations for reherniations by 81%* with its Barricaid Annular Closure Device. Today, the company announced that Michael Briseño, MD of North Texas Orthopedics […]

BOSTON, MA – September 2, 2025  – Intrinsic Therapeutics, Inc., a medical technology company committed to redefining the standard of care for lumbar discectomy patients with large annular defects by reducing reoperations for reherniations by 81%* with its Barricaid Annular Closure Device, announced today that, for the first time, the Barricaid device has been successfully […]

BOSTON – August 18, 2025 – Intrinsic Therapeutics, Inc., a medical technology company committed to redefining the standard of care for lumbar discectomy patients with large annular defects by reducing reoperations for reherniations by 81%* with its Barricaid Annular Closure Device, announced today the appointment of industry veterans Mike Lytle and Dave Decker as Vice President of Sales, […]

Discectomy is a common outpatient spinal procedure, but for patients with large annular defects (>5mm), outcomes can be unpredictable and sometimes devastating. In a session at Becker’s 22nd Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, leaders explained how ASCs can improve patient outcomes, reduce reoperations and strengthen financial performance by […]

BOSTON, MA – June 25, 2025 – Intrinsic Therapeutics, a medical technology company committed to redefining the standard of care for lumbar discectomy patients with large annular defects by reducing reoperations for reherniations by 81%* with its Barricaid Annular Closure Device, announced today that the device was implanted for the first time via an endoscopic […]

BOSTON, MA – June 19, 2025 – Intrinsic Therapeutics, a medical technology company committed to redefining the standard of care for lumbar discectomy patients with large annular defects by reducing reoperations for reherniations by 81%* with its Barricaid Annular Closure Device, announced today that the International Society for the Advancement of Spine Surgery (ISASS) has […]

BOSTON, MA – April 10, 2025 – Intrinsic Therapeutics, a medical technology company driving to change the standard of care for lumbar discectomy patients with large annular defects by reducing reoperations for reherniations by 81%* with its Barricaid Annular Closure Device, today announced the appointment of Keith Valentine as President and Chief Executive Officer. Mr. […]

BOSTON, MA – November 12th 2024 (via PR NewsWire) – Intrinsic Therapeutics, a medical technology company driving to change the standard of care for lumbar discectomy patients with large annular defects by reducing reoperations for reherniations by 81% with its Barricaid Annular Closure Device, announced today that the Centers for Medicare & Medicaid Services (CMS) issued […]

BOSTON, MA – October 24, 2024 via PRNewsWire (Link) – Intrinsic Therapeutics, Inc., a medical device company focused on preventing reherniation and reoperation following lumbar discectomy to treat herniated discs, announced today that the American Medical Association (AMA) CPT Editorial Panel has accepted the addition of a new Category 1 CPT Code for bone anchored […]